Ikarian Capital’s Avalo Therapeutics AVTX Stock Holding History

Ikarian Capital’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.37M	Buy	+158,500	New	+$2.48M	0.19%	93

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Ikarian Capital's AVTX Position: Q1 2026 in Review

Ikarian Capital sold out of Avalo Therapeutics (AVTX) in Q1 2026, closing a stake of 31,106 shares — an estimated $486K sold.

Ikarian Capital first reported a position in AVTX in Q4 2019 and held it in 18 quarters. The position peaked at $9.22M in Q3 2024. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

Ikarian Capital reported no remaining Avalo Therapeutics position as of Q1 2026 after selling out during the quarter.
Ikarian Capital sold 31,106 Avalo Therapeutics shares in Q1 2026, an estimated $486K.
Ikarian Capital first reported a position in Avalo Therapeutics in Q4 2019 and held it in 18 quarters.
Ikarian Capital's Avalo Therapeutics position peaked at $9.22M in Q3 2024.
97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.